BioInformant

Your Global Leader in Stem Cell Market Research

Home » Exosomes » Page 18

Explosion of Interest In Exosome Technologies And Companies Leading The Charge

By Leave a Comment

Although long overlooked, exosomes are rapidly gaining momentum as a novel strategy for accessing the therapeutic effects of stem cells without the risks and difficulties of administering the cells to patients.

Exosome Companies

In this article:

Exosome Technologies and Companies

Exosomes have enormous potential for use as biomarkers in non-invasive tests, vehicles for drug delivery, and active agents in cosmeceutical products.

Exosome Therapeutics and Diagnostics

Exosomes are valuable because they reduce many of the risks associated with traditional cell therapies. On the therapeutic front, companies investing in exosome-based therapies include:

  • Anjarium Biosciences
  • Capricor Therapeutics
  • Codiak Biosciences
  • Creative Medical Technology Holdings
  • Everkine Corporation
  • Evox Therapeutics
  • Exogenus Therapeutics
  • Kimera Labs
  • ReNeuron
  • Unicyte AG, a subsidiary of Fresenius Medical Care [Read more…]

Exosome Market Forces

By 2 Comments

Exosome-related technologies have been developing rapidly over the past few years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine and regenerative medicine.

In particular, cancer derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection. [Read more…]

Funding Flows Freely into Exosome Therapeutics

By 1 Comment

Because the therapeutic applications of stem cell exosomes are expanding, innovation within the market is also accelerating. New trends have emerged, including the use of stem cell exosomes as diagnostic tools and cell-free therapeutics. Additionally, numerous life science companies are offering tools and reagents to support exosome research.

Similarly, techniques for large-scale clinical-grade manufacture of stem cell exosomes is becoming a focal point within the industry, as highlighted by a recent partnership between RoosterBio and Exopharm, as well as Lonza’s intentions to enter the market through it recent acquisitions of HansaBioMed Life Sciences and investment into Exosomics made in May 2017. [Read more…]

Avalon GloboCare Subsidiary GenExosome Expands Exosome Operations into the U.S.

By Leave a Comment

Avalon GlobocareFREEHOLD, NJ–(February 14, 2018) – Avalon GloboCare Corp. (OTCQB: AVCO), a leading global developer of cell-based technologies, announced today that its majority-owned subsidiary, GenExosome Technologies Inc. (GenExosome), has formally launched its U.S. operations, with plans to market and distribute its proprietary Exosome Isolation Systems from its new headquarters in Ohio. The Company also announced plans to develop proprietary diagnostic and therapeutic products leveraging its exosome technology. The Company has already begun hiring personnel for marketing and customer fulfillment.

Exosomes are tiny, subcellular, membrane-bound vesicles, measuring 30-150 nm in diameter, that are released by almost all cell types. Exosomes can carry membrane and cellular proteins, as well as genetic materials that are representative of the cell of origin. Profiling various bio-molecules in exosomes may serve as useful biomarkers for a wide variety of diseases.

GenExosome’s Exosome Isolation Systems are designed to be used by researchers for biomarker discovery and clinical diagnostic development, as well as the advancement of targeted therapies. Currently, research kits and services are available to isolate exosomes or extract exosomal RNA/protein from serum/plasma, urine and saliva samples. GenExosome is seeking to decode proteomic and genomic alterations underlying a wide-range of pathologies, thus allowing for the introduction of novel non-invasive liquid biopsies. [Read more…]

Salivary EVs, Exosomes, and the Future of Non-Invasive Diagnostics

By 1 Comment

Oasis DiagnosticsI had the honor of interviewing Paul D Slowey, PhD, CEO of Oasis Diagnostics® Corporation, a company specializing in non-invasive saliva based technology for rapid testing, sample collection, and molecular diagnostics. Dr. Slowey is also the Organizer of the North American Saliva Symposium (NASS).

In this interview, we discuss his unique background, the rise of extracellular vesicles (EVs) and exosomes as diagnostic tools, advantages of saliva over other bodily fluids, and current and future applications for saliva-derived EVs and exosomes. [Read more…]

BioInformant's World-Class Clients

Shopping cart0
There are no products in the cart!
Continue shopping
0